Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Препарат Калквенс достиг первичной конечной точки по эффективности в прямом сравнительном исследовании с препаратом ибрутиниб у пациентов с хроническим лимфоцитарным лейкозом
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Пресс-релиз компании АстраЗенека от 25 января 2021. Режим доступа: https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-.... Ссылка активна на 25.01.2021 [Press reliz kompanii AstraZeneka ot 25 ianvaria 2021. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-.... Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-.... Accessed: 25.01.2021 (In Russian)].
2. Available at: https://clinicaltrials.gov. NCT02477696. Accessed: 25.01.2021.
3. Dreger P, Ghia P, Schetelig J, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 2018; 132 (9): 892–902.
4. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQR)–Patient Version. Available at: https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq. Accessed: January 2021.
5. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncol 2019; 5 (12): 1749–68.
6. Jain N, et al. Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies. Blood 2015; 126: 871.
7. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 2016; 9 (21).
2. Available at: https://clinicaltrials.gov. NCT02477696. Accessed: 25.01.2021.
3. Dreger P, Ghia P, Schetelig J, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 2018; 132 (9): 892–902.
4. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQR)–Patient Version. Available at: https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq. Accessed: January 2021.
5. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncol 2019; 5 (12): 1749–68.
6. Jain N, et al. Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies. Blood 2015; 126: 871.
7. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol 2016; 9 (21).
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.